Invasive actinomycosis: surrogate marker of a poor prognosis in immunocompromised patients  by Pierre, Isabelle et al.
International Journal of Infectious Diseases 29 (2014) 74–79Invasive actinomycosis: surrogate marker of a poor prognosis
in immunocompromised patients
Isabelle Pierre a, Virginie Zarrouk a, Latifa Noussair b, Jean-Michel Molina c,d,
Bruno Fantin a,d,*
a Service de Me´decine Interne, Hoˆpital Beaujon, Assistance Publique Hoˆpitaux de Paris, 100 boulevard du ge´ne´ral Leclerc, 92110 Clichy, France
b Service de Microbiologie, Hoˆpital Beaujon, Assistance Publique Hoˆpitaux de Paris, Clichy, France
c Service de Maladies Infectieuses et Tropicales, Hoˆpital Saint Louis, Assistance Publique Hoˆpitaux de Paris, Paris, France
dUniversite´ Paris-Diderot, Sorbonne Paris Cite´, Paris, France
A R T I C L E I N F O
Article history:
Received 21 March 2014
Received in revised form 12 June 2014
Accepted 13 June 2014
Corresponding Editor: Eskild Petersen,
Aarhus, Denmark
Keywords:
Actinomyces sp
Immunosuppression
Beta-lactams
Surgery
S U M M A R Y
Objectives: Actinomycosis is a rare disease favored by disruption of the mucosal barrier. In order to
investigate the impact of immunosuppression on outcome we analyzed the most severe cases observed
in patients hospitalized in three tertiary care centers.
Methods: We reviewed all cases of proven invasive actinomycosis occurring over a 12-year period
(1997 to 2009) in three teaching hospitals in the Paris area.
Results: Thirty-three patients (16 male) were identiﬁed as having an invasive actinomycosis requiring
hospitalization. The diagnosis was made by microbiological identiﬁcation in 26 patients, pathological
examination in eight patients, and by both methods in one. Twenty patients (61%) were
immunocompromised. Actinomycosis localization was abdominal or pelvic in 17 patients, thoracic in
11, cervicofacial in three, and neurological in two. Twenty patients (61%) underwent surgery. All strains
were susceptible to amoxicillin. All patients were treated with a beta-lactam antibiotic, for a median
length of 82 days. Twenty-eight patients (85%) were considered as cured. Overall mortality at hospital
discharge was 21% (7/33). Mortality was higher in immunocompromised patients (7/20; 21%) compared
to non-immunocompromised patients (0/13) (p = 0.027). However, six of seven deaths were directly
related to the underlying disease.
Conclusions: Actinomycosis is a cause of severe infection in immunocompromised patients and a
surrogate marker of a poor prognosis in this speciﬁc population
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The genus Actinomyces is a heterogeneous group of Gram-
positive bacteria, mainly anaerobic facultative or microaerophilic
rods with various degrees of branching. Actinomyces species are
frequently found as members of the normal microbiota in open
cavities, especially the oropharynx, upper respiratory tract,
gastrointestinal tract, and female genital tract.1
Among the different species of Actinomyces identiﬁed, Actino-
myces israelii is the most commonly encountered in clinical
infections; other species can also produce infection in man, such as* Corresponding author. Tel.: +33 1 40 87 58 90; fax: +33 1 40 87 10 81.
E-mail address: bruno.fantin@bjn.aphp.fr (B. Fantin).
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license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Actinomyces naeslundii, Actinomyces viscosus, and Actinomyces
odontolyticus.1
The clinical presentation varies according to the anatomical
location. Classical features are cervicofacial cellulitis in patients
with poor dental hygiene,2 thoracic infections after esophageal
lesion,3,4 abdominal infection after surgery or gastrointestinal
perforation,5 and pelvic infection favored by the presence of an
intrauterine device (IUD).1 Cases mimicking cancer are frequently
reported because of the torpid presentation of the infection.
Penicillin is the treatment of choice, and should be adminis-
tered for a long duration (3–12 months), according to the
anatomical location.1
Actinomyces have a low virulence potential and can cause
invasive disease only when the normal mucosal barrier is
disrupted. Therefore, because of this low virulence, we hypothe-
sized that actinomycosis could be an opportunistic infection inciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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this point, we analyzed the most severe cases of actinomycosis
observed in three tertiary care hospitals and studied the
relationship between immunosuppression and outcome.
2. Patients and methods
We recorded all cases of invasive actinomycosis diagnosed in
three tertiary care and teaching hospitals in the Paris area (Beaujon
hospital, 500 beds; Saint-Louis hospital, 700 beds; Saint Joseph
hospital, 600 beds) that occurred over a 12-year period (January
1997 to March 2009).
Invasive actinomycosis was deﬁned as a deep-seated infection
with an identiﬁcation of Actinomyces from the site of infection by
microbiological and/or a pathological examination. A deep
microbial sample growing Actinomyces spp was required. Identiﬁ-
cation to the species level was done using morphological and
biochemical characteristics, and when needed by sequencing
methods. A biopsy leading to a pathological diagnosis of
actinomycosis was considered; the presence of actinomycotic
granules in exudates or in histological sections of tissue was highly
indicative of actinomycosis.
All adult patients with reliable medical charts and meeting
these criteria were included. Outpatients or patients with
incomplete medical records, and patients with samples growing
Actinomyces sp without a related focus of infection or with a
superﬁcial infection were excluded (Figure 1).
For each patient, demographic characteristics, underlying
diseases, clinical and radiological manifestations, microbiological
results, and treatment and outcome data were collected retro-
spectively and reviewed.
Statistical analyses were done with Epi Info 3.5.1. Means were
compared with a Mann–Whitney test. Qualitative variables were
compared with a Fisher’s exact test.Figure 1. Screening of the patients3. Results
3.1. Study patients
As shown in Figure 1, 97 patients were screened for
actinomycosis by pathology or bacteriology. Data were missing
for 30 of them (mostly outpatients). Of the remaining 67 medical
records that were examined, the clinician did not retain the
diagnosis of infection due to actinomycosis in 19. These cases were
systematic cultures of vaginal tract samples from the gynecology
ward, or of bronchoalveolar lavage samples from pulmonary
transplanted patients.
Forty-eight patients met the criteria for actinomycosis, but
15 were considered to have focal and superﬁcial infections and
were ﬁnally excluded. The remaining 33 patients were considered
to have an invasive actinomycosis and represented the study
population (Table 1).
3.2. General condition and presentation
The median age at presentation was 47 years. Seventeen
patients were female. Twenty patients (61%) had at least one
severe underlying condition and were considered as immuno-
compromised: seven had solid cancer, six were receiving
immunosuppressive treatments, ﬁve had uncontrolled diabetes
mellitus, ﬁve had a hematological malignancy, four had an
autoimmune disease, two were bone marrow transplant
recipients, and one had an HIV infection with a CD4 count of
<200 cells/mm3 (Table 1). Local trauma was reported in six
patients (including previous surgery in three); an IUD was
reported in ﬁve of the 17 patients with abdominal actinomyco-
sis. Twenty-six patients (79%) had fever and 15 (45%) had lost
weight. Focal symptoms varied according to the anatomical
location of the infection. with invasive actinomycosis.
Table 1
Clinical presentation of 33 patients with invasive actinomycosis
Age, years, median (range) 47 (21–82)
Sex ratio, male/female 16/17
Underlying conditions, n
Cancer 7
Immunosuppressive treatment 6
Diabetes mellitus 5
Hematological malignancy 5
Autoimmune disease 4
HIV infection 1
Bone marrow transplantation 2
Disease location, n
Abdomen or pelvis 17
Central nervous system 2
Thorax 11
Oral and cervicofacial area 3
General symptoms, n
Fever 26
Weight loss 15
Diagnostic procedure, n
Surgical biopsy 20
Bronchoalveolar lavage 6
Pleural puncture 2
Fistulized abscess examination 2
Biopsy guided by radiology 3
Diagnostic method, n
Microbiology alone 25
Pathology alone 7
Both 1
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An abdomino-pelvic location was the most frequent (n = 17).
Fifteen patients had peritonitis or abdominal abscesses: two had
hepatic abscess, one had splenic abscess, two had postoperative
collections, four had peritonitis (including two postoperative
peritonitis, one hepatic abscess, and one pelvic abscess), three had
appendicitis, one had retroperitoneal abscess, one had infected
pancreatic necrosis after acute pancreatitis, and one had
abscessed signoiditis. Two cases of pelvic infection in women
presented as pseudotumor. Both cases had an IUD and no
gynecological follow-up.
Thoracic actinomycosis was recorded in 11 patients. Most
cases presented as organized pneumonia (8/11); the other
patients had infection of a previous post-surgical cavity (1/11),
sternal osteitis after radiotherapy (1/11), and pyopneumothorax
(1/11). The two patients with central nervous system involve-
ment had brain abscesses. Among three patients with cervical
and oral actinomycosis, one had cervicofacial cellulitis, one had
cervical postoperative abscess, and one had infected palatal
necrosis.Table 2
Microbiological identiﬁcation and susceptibility study of clinical isolates of Actinomyc
Actinomyces susceptibility to different antibioticsa
Species (number of isolates) AMX IPM MTR 
Actinomyces spp (n = 3) 3/3a 3/3 0/2 
Actinomyces odontolyticus (n = 8) 8/8 8/8 0/8 
Actinomyces meyeri (n = 9)b 7/7 6/6 0/6 
Actinomyces israelii (n = 2) 2/2 2/2 1/2 
Actinomyces naeslundii (n = 3) 3/3 3/3 0/2 
Actinomyces neuii (n = 1) 1/1 1/1 NT 
Total (n = 26) 24/24 23/23 1/20 
AMX, amoxicillin; IPM, imipenem; MTR, metronidazole; RIF, rifampin; VA, vancomycin; 
NT, not tested.
a Proportions are the number of susceptible isolates/number of isolates tested for a 
b Suceptibility testing was not available for two patients with A. meyeri infection.3.4. Diagnosis
Microbiological examination of samples was performed in all
but one patient. The samples grew Actinomyces in 26 cases
(81%). Pathological examination of samples was performed in
18 patients. For eight of them (44%) the diagnosis of actinomy-
cosis was retained. Both procedures were positive in only one
patient.
3.5. Microbiology
Actinomyces identiﬁcation was available in 26 patients
(Table 2). Actinomyces meyeri and A. odontolyticus were the
most frequent species. In three cases, identiﬁcation to the
species level was not done by standard methods. The results of
susceptibility testing are shown in Table 2. All isolates were
susceptible to amoxicillin, imipenem, vancomycin, rifampin, and
tetracycline. Twenty-six (79%) patients had polymicrobial
infections.
3.6. Treatment
All patients received effective empiric and deﬁnite antibiotic
therapy with a beta-lactam (Table 3). Amoxicillin associated or
not with clavulanic acid was administered in 91% of patients who
received antibiotics for more than 48 h. The mean duration of
antibiotic use was 105 days, with a median of 82 days. The range of
antibiotic treatment duration was very wide, from 2 to 547 days.
Three patients were treated for less than 10 days: the ﬁrst died
2 days after the start of treatment due to cerebral hypertension,
the second underwent a surgical resection of a thoracic
actinomycosis revealed by a massive hemoptysis, and the third
had appendicitis. At the other extreme, three patients were
treated for more than 6 months: one had a liver abscess, one had
pneumonia with leukemia, and one had hepatic and pelvic abscess
with compression of the urinary tract.
Twenty (61%) patients underwent surgery (Table 4). Thirteen
among 17 patients with abdominal actinomycosis (76%) had
surgery: ﬁve had peritonitis at onset, two had an occlusive
syndrome, one had compression of the urinary tract, one had a
voluminous retroperitoneal abscess, one had septic shock, and
three failed therapy despite adequate medical treatment
combined in two cases with radiological drainage. All four
patients with abdominal actinomycosis who did not undergo
surgery received medical treatment combined with computed
tomography-guided drainage.
The mean duration of antibiotic treatment was not signiﬁcantly
different in patients who underwent surgery compared to those
who did not (84 days vs. 136 days, p = 0.23).es
RIF VA ERY CM TE FQ
2/2 2/2 2/2 2/2 2/2 NT
7/7 7/7 4/4 5/6 3/3 0/5
5/5 6/6 3 /4 4/4 1/1 0/5
1/1 2/2 NT 2/2 1/1 0/1
NT 2/2 1/1 2/2 2/2 1/2
1/1 1/1 1/1 0/1 1/1 NT
16/16 20/20 11/12 15/17 10/10 1/13
ERY, erythromycin; CM, clindamycin; TE, tetracycline; FQ, oﬂoxacin or levoﬂoxacin;
given antibiotic.
Table 3
Antibiotic treatment in 33 study patients with invasive actinomycosis
Antibiotic regimens Duration, days, median (range)
All antibiotics 82 (2–547)
Amoxicillin 168 (16–547)
Amoxicillin/clavulanic acid 22 (5–182)
Other beta-lactams 17 (2–133)
Others antibiotics 0
Table 5
Clinical outcome in 33 patients with invasive actinomycosis
Cured of infection Not cured of infection
Alive 26 (79%) 0 (0%)
Without relapse 26
With relapse 0
Dead 2 (6%) 5 (15%)
Cerebral hypertension 0 1
Evolution of underlying cancer or
hematological malignancy
1 4
Chronic respiratory insufﬁciency 1 0
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The median follow-up was 199 days (range 2–3832 days). The
overall mortality at hospital discharge was 21% (7/33). All deaths
occurred among immunocompromised patients (7/20 deaths in
immunocompromised vs. 0/13 in non-immunocompromised
patients, p = 0.027) (Table 5). Twenty-eight patients (85%)
were considered cured of infection by clinicians because of the
absence of relapse after the end of antibiotic treatment. Two of
these 28 patients died from their underlying diseases (chronic
respiratory failure and lung cancer) after they had completed
treatment. The ﬁve other patients died before the end of antibiotic
treatment and were thus considered as failure. However, only one
death (1/5) was directly related to actinomycosis, in a patient with
a voluminous brain abscess with cerebral hypertension who died
2 days after the commencement of antibiotics. The last four (4/5)
patients died from the evolution of underlying cancer or
hematological malignancy. Overall, 26/33 (79%) patients were
cured of infection and alive at hospital discharge.
4. Discussion
We have described 33 patients with different locations of
invasive actinomycosis who were diagnosed and treated during a
recent period. We excluded superﬁcial actinomycosis, such as
cutaneous abscess, for which the outcome was expected to be goodTable 4
Surgical treatment in 20 patients with invasive actinomycosis
Sex Age Localization Presentation 
F 52 Abdominal Obstructive syndrome with pelvic tumor 
F 45 Abdominal Septic shock 2 days after initiation of antibiotics for
hepatic and pelvic abscess (with compression of the
urinary tract)
F 63 Abdominal Right pelvic abscess with acute abdomen 
F 35 Abdominal Vesical tumor with compression of the urinary trac
F 54 Abdominal Hepatic abscess with signs of peritonitis/acute abdom
M 28 Abdominal Obstructive syndrome with pelvic abscess 5 days af
cholecystectomy and removal of ileocolic anastomo
M 42 Abdominal Appendicitis 
F 62 Abdominal Septic shock 4 days after hysterectomy and ovariecto
for ovarian cancer
M 40 Abdominal Voluminous perineal abscess 
F 54 Abdominal Septic shock 7 days after antimicrobial therapy for
abscessed sigmoiditis
F 40 Abdominal Torsion of teratoma 
F 32 Abdominal Appendicitis 
M 57 Abdominal Persistent fever despite radiological drainage after
15 days of antimicrobial therapy in patient with
pancreatic necrosis after acute pancreatitis
M 46 Thoracic Empyema after pneumectomy in a patient with can
M 51 Thoracic Hemoptysis with pulmonary mass 
F 82 Thoracic Sternal osteoradionecrosis after radiotherapy for bre
cancer
F 72 Thoracic Pneumopathy with mass blocking left stem bronchu
F 32 Cerebral Brain abscess 
M 29 Cervicofacial Palatal necrosis in patient with acute leukemia 
F, female; M, male.with a short course of antibiotics associated or not with minimal
surgery.
So far, the largest original clinical series reported at best
25 patients in 12 years (Table 6). Males have tended to be more
affected than females,1,4,6 a feature that was not conﬁrmed in our
study, in which the sex ratio was 1:1. This discordance may be
explained by poor dental hygiene and more local trauma in males
in earlier years. Poor dental hygiene was involved in only four of
our patients. Improvements in oral and dental hygiene are also
linked to the decrease in number of cervicofacial actinomycosis.
Cervicofacial actinomycosis affected only 9% of our patients,
whereas it represented up to 55% of cases in historic series.3 This
trend has already been noted by Pulverer et al.2 The two German
reference laboratories received 1218 clinical specimens responsi-
ble for cervicofacial actinomycosis between 1972 and 1984
(12 years) and only 778 between 1985 and 1998 (13 years). In
addition, the majority of our patients were immunocompromised
due to the extensive use of chemotherapy for cancer and
hematological malignancy. Because of improved dental hygiene
on the one hand and increased proportions of immunocompro-
mised patients on the other, actinomycosis is becoming an
opportunistic infection of the immunocompromised in our tertiary
care setting.Type of surgery Outcome
Colostomy and surgical biopsy Cure
Drainage of multiple abscesses, colostomy,
suture of vesical ﬁstula and hysterectomy,
ovariectomy
Cure
Ovariectomy and abscess drainage Cure
t Tumor ablation via coelioscopy Cure
en Abscess drainage Cure
ter
sis
Abscess drainage and colectomy Cure
Appendectomy Cure
my Douglas’ abscess drainage and peritoneal
cleaning
Progression of cancer;
death
Abscess drainage Cure
Left colectomy and Hartmann diversion Cure
Appendectomy
Appendectomy Cure
Necrosectomy and cholecystectomy Cure
cer Surgical cleaning Cure of infection;
death 6 months later
Mass excision Cure
ast Sternum resection Cure
s Lobectomy Cure
Puncture Death due to engagement
Necrotic tissue removal Death on treatment due
to acute leukemia
Table 6
Review of the largest clinical series of actinomycosis in the literature
Authors [Ref.] Description of the series Sex ratio Period Treatment Outcome
Pulverer et al. [2] 1997 cases of cervicofacial actinomycosis:
microbiological description only
1376 M/574 F
47 NS
1972–1999 NS NS
Baik et al. [3] 25 cases of thoracic actinomycosis 19 M/6 F 1985–1997 11 medical only
14 medical + surgical
11 alive
1 dead
13 NS
Kinnear and MacFarlane [4] 19 cases of thoracic actinomycosis 15 M/4 F 1974–1990 12 medical only
7 medical + surgical
Median duration of ATB: 6 weeks
(range 1–24 weeks)
19 alive
Choi et al. [11] 22 cases of abdominal actinomycosis 2 M/20 F 2000–2006 21 medical
Duration of ATB: 1 to 6 months
1 NS
22 alive
Poey et al. [12] 9 cases of thoracic actinomycosis 6 M/3 F NS NS NS
Hsieh et al. [13] 17 cases of thoracic actinomycosis 13 M/4 F 1984–1990 8 medical
9 medical + surgical
Duration of ATB: at least 2–3 months
17 alive
Sung et al. [27] 23 cases of abdominal actinomycosis 5 M/18 F 1994–2010 23 medical
Duration of ATB: 4.2 months
(range 0.5–7 months)
23 alive
M, male; F, female; NS, not speciﬁed; ATB, antibiotic therapy.
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features. Most authors7–10 have reported actinomycosis mimicking
cancer with a slow evolution, while an infectious and more acute
presentation has been less common.5 In contrast, infectious
presentations were most frequent in our study: most of our
patients had fever regardless of the location of the actinomycosis.
The study patients were therefore suspected of having an
infectious process (pneumonia, abdominal abscess, etc.) according
to the location of the process.
Abdominal involvement accounted for half of the cases.
Previous descriptions have reported cases of women who had
had an IUD for a long time and who developed an abdominal mass
suggestive of gynecological cancer. Only two of our patients had
such a pseudotumoral form; both had an IUD and none had
attended gynecological follow-up. Peritonitis or peritoneal abscess
was in fact the most frequent presentation in our patients with
abdominal involvement. In a recent study Choi et al.11 reported
22 cases with abdominal actinomycosis; 11 presented as an
infectious process (two diverticulitis, ﬁve tubo-ovarian abscess,
three appendicitis, and one pelvic abscess).
All our patients with thoracic involvement had infectious
presentations. Various radiological features have been reported.
All patients in the study by Poey et al.12 had alveolar condensation,
which was excavated in two of nine patients. Hsieh et al.13
described a mass in ﬁve patients, pneumonia in four patients,
abscess in four patients, and empyema in two patients. For Baik
et al.,3 a mass, nodules, and alveolar condensation were the most
frequent features. Our results are similar, with alveolar condensa-
tion (with or without excavation) found in 73% of the patients.
Complications of thoracic actinomycosis were less frequent in our
series, with only one pyopneumothorax and one hemoptysis,
which have previously been reported to be very frequent by Baik
et al.3 (72%) and Hsieh et al.13 (43%).
In the majority of cases Actinomyces were isolated in
combination with other bacteria (79% of our patients had
polymicrobial infections). In our series, the ﬁrst three species
were A. meyeri, A. odontolyticus, and A. naeslundii. There was no link
between species and anatomical location.
Susceptibility of Actinomyces to beta-lactams is the rule, with
the exception of rare cases; Metgud et al.14 reported a case of
cutaneous actinomycosis due to A. viscosus that was resistant to
penicillin and treated with co-trimoxazole. Smith et al.15 described
susceptibility of six different Actinomyces (A. israelii, A. gerencser-
iae, A. turicensis, A. funkei, A. graevenitzii, and A. europaeus) to12 antibiotics. All were sensitive to penicillin and amoxicillin. A
decreased susceptibility to piperacillin/tazobactam has been noted
for some A. turicensis, A. funkei, and A. europaeus, and to
erythromycin for some A. europaeus and A. turicensis strains. All
isolates were resistant to ciproﬂoxacin. Our ﬁndings were similar:
all isolates were fully susceptible to amoxicillin, piperacillin, and
imipenem. Ninety-two percent of isolates were susceptible to
erythromycin and the majority were resistant to ﬂuoroquinolones.
In spite of the fact that sulfonamides,16 with penicillin, were the
ﬁrst effective treatment described for actinomycosis, co-trimox-
azole has rarely been tested. Ninety-one percent of our patients
were treated with amoxicillin alone or in combination with
clavulanic acid.
Many authors including Russo1 state that it is necessary to
treat this disease with high doses of penicillin and for a
prolonged period of time. Russo proposed 18–24 million units of
penicillin intravenously for 2 to 6 weeks followed by oral
therapy with amoxicillin (500 mg four times a day) for 6–12
months. This compliant treatment with high doses of antibiotic
and for a long time was based on the description of relapse
or failure in older studies.6 In less extensive cases, less
aggressive therapy might be required. Many authors have
reported cases cured with a shorter duration of antibiotic
therapy.4,13,16–27 Choi et al.26 reported a series of 28 thoracic
actinomycosis patients: 27 of the 28 patients were cured with a
median course of antibiotics of 2 days (range 0–18 days)
intravenously and 167 days (range 76–412 days) orally in those
treated with antibiotics alone, and of 8 days (range 3–17 days)
intravenously and 150 days (range 0–534 days) orally in those
treated with both antibiotics and surgery. Sudhakar and Ross17
reported two cases of actinomycosis treated successfully with
9 days and 8 weeks, respectively, of antibiotics; the ﬁrst patient
had 9 days of antibiotics for cervicofacial cellulitis and the
second had 8 weeks of penicillin for actinomycosis of the
esophagus.
In our study, patients were treated for a median of 82 days and
28/33 (85%) patients were cured of their infection; 26 were cured
and alive at hospital discharge. No relapse was observed. In fact, in
only one case was clinical failure related to uncontrolled infection
due to a brain abscess. Our results are in agreement with those
reported by Choi et al.26 and Sudhakar and Ross17 and indicate that
a shorter course of antibiotics is a possible option depending on
the anatomical location, inoculum size, immunosuppression, and
clinical evolution under therapy.
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was clearly related to underlying diseases, as six of seven deaths
were not directly related to infection. However, the occurrence of
an invasive actinomycosis in an immunocompromised patient
should certainly be considered as a surrogate marker of a poor
prognosis. Therefore, the severity of underlying disease rather than
the duration of antibiotic therapy appears to be a key determinant
of clinical cure.
Limitations of this series are the usual biases of retrospective
studies. In particular, there was a selection bias towards more
severe cases in the frailest patients due to the tertiary care
recruitment. However, analysis of the outcome in this population
can more easily be extrapolated than results obtained in less
invasive cases and immunocompetent patients.
In conclusion, our study showed that immunosuppression
was clearly associated with a more lethal outcome. This study
also conﬁrmed that surgery or drainage is part of the treatment
and that a short course of antibiotic therapy, depending on the
clinical presentation and outcome, might be considered.
Amoxicillin remains the antibiotic of choice unless a poly-
microbial infection is documented and requires a wider
antibacterial spectrum.
Conﬂict of interest: All authors declare no conﬂict of interest.
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